Alternative medicine

Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option

Retrieved on: 
Tuesday, May 7, 2019
Surgery, Practice Management, Health, Alternative medicine, Biotechnology, Clinical trials, Hospitals, Pharmaceutical, Research, Science, Managed care, Health, Articles, Clinical research, Clinical pharmacology, Pharmaceutical industry, Piper Jaffray, U.S. Bancorp, Clinical trial

We believe in Elligos mission to help all patients have the best access to clinical trials as a care option, said Tom Schnettler , managing director at Piper Jaffray Merchant Banking and a new Elligo board member.

Key Points: 
  • We believe in Elligos mission to help all patients have the best access to clinical trials as a care option, said Tom Schnettler , managing director at Piper Jaffray Merchant Banking and a new Elligo board member.
  • The goal is to drive clinical trial efficiency through innovation, said John Potthoff, PhD , CEO of Elligo.
  • Elligo Health Research , an integrated research organization (IRO), accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack clinical technology and our Goes Direct approach.
  • In doing so, we expand the base of physicians and their patients who otherwise would not participate in clinical trials.

FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids

Retrieved on: 
Tuesday, May 7, 2019
Health, Alternative medicine, Biotechnology, Pharmaceutical, Natural Resources, Other Natural Resources, Research, Science, FSD

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (FSD Pharma or FSD) and Solarvest BioEnergy Inc. (TSX-V: SVS) (Solarvest), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement.

Key Points: 
  • FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (FSD Pharma or FSD) and Solarvest BioEnergy Inc. (TSX-V: SVS) (Solarvest), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement.
  • Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids.
  • Upon successful development of proof of concept, Solarvest and FSD Pharma intend to enter into a license agreement under which Solarvest will grant FSD Pharma an exclusive, worldwide license over any use of prescription drugs that can treat diseases affecting the central nervous system.
  • Pursuant to the agreement, the two companies have made the following investments into one another:
    a) FSD Pharma has issued 10,000,000 class B subordinate voting shares in the capital of FSD Pharma shares to Solarvest at a price of $0.30 per FSD share;
    b) Solarvest has issued 3,000,000 units of Solarvest units to FSD Pharma at a price of $0.20 per unit.

TherapeuticsMD Announces First Quarter 2019 Financial Results

Retrieved on: 
Monday, May 6, 2019
Women, Health, Alternative medicine, Biotechnology, Pharmaceutical, Consumer, General Health, Managed care, Operating systems, Software, Microblogging, Real-time web, Social media, Text messaging, Twitter, World Wide Web

This is an increase of approximately 58% in prescription volume for the first quarter of 2019 as compared to the fourth quarter of 2018.

Key Points: 
  • This is an increase of approximately 58% in prescription volume for the first quarter of 2019 as compared to the fourth quarter of 2018.
  • Net revenues for the first quarter of 2019 were approximately $3.9 million, compared with net revenues of approximately $3.8 million for the prior years quarter.
  • R&D expenses for the first quarter of 2019 were approximately $6.3 million, compared with approximately $7.0 million for the prior years quarter.
  • To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Quanterix’ Simoa Technology Powers More Than 85 Percent of Neurofilament Light Biomarker Research to be Unveiled at American Academy of Neurology Annual Meeting

Retrieved on: 
Monday, May 6, 2019
Health, Alternative medicine, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Research, Other Science, Science, General Health, Biomarkers, Branches of biology, Biology, Life sciences

Nf-L has the ability to create new testing modalities for detection and treatment across numerous degenerative disease states, including some of the most difficult-to-detect conditions.

Key Points: 
  • Nf-L has the ability to create new testing modalities for detection and treatment across numerous degenerative disease states, including some of the most difficult-to-detect conditions.
  • Our Simoa technology helped researchers measure Nf-L accurately in blood for the first time, and its incredibly rewarding to see the continued impact of our technology on these and many other studies.
  • Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health.
  • The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

Atlas Chiropractic in Sheridan, Wyoming Releases a New Website Design for Their Chiropractic Clinic

Retrieved on: 
Monday, May 6, 2019
Chiropractic, Medicine, Manual therapy, Alternative medicine, Health care, Veterinary chiropractic, Spinal adjustment

SHERIDAN, Wyo., May 6, 2019 /PRNewswire-PRWeb/ -- Sheridan Chiropractor , Dr. Colin Hardy of Atlas Chiropractic is pleased to announce their brand new website design.

Key Points: 
  • SHERIDAN, Wyo., May 6, 2019 /PRNewswire-PRWeb/ -- Sheridan Chiropractor , Dr. Colin Hardy of Atlas Chiropractic is pleased to announce their brand new website design.
  • At Atlas Chiropractic, Dr. Hardy is incredibly passionate about empowering each patient with the knowledge and resources to take control of their health.
  • The amazing care provided since the practice's establishment is what makes Atlas Chiropractic one of the most sought after chiropractic centers in Wyoming .
  • Dr. Hardy provides chiropractic care, pediatric chiropractic care, spinal decompression, sports injury rehabilitation, auto accident and personal injury rehabilitation and more.

Advancing Early Diagnosis and Treatment of Lyme Disease and Vector-Borne Illnesses: Thought Leadership & Innovation Foundation Researchers Home-In on Solutions

Retrieved on: 
Monday, May 6, 2019
Health, Alternative medicine, Infectious diseases, Other Health, Philanthropy, Parenting, Research, Other Science, Consumer, Family, Science, Foundation, Epidemiology, Insects in culture, Arthropods, Parasitology, Medical specialties, Infectious diseases, Vector, Louse, Flea, Infection, Rickettsioses

Unreliable testing for these diseases, transmitted by ticks, fleas, body lice, flies and other organisms known as vectors, often leaves those who are infected without a diagnosis or treatment.

Key Points: 
  • Unreliable testing for these diseases, transmitted by ticks, fleas, body lice, flies and other organisms known as vectors, often leaves those who are infected without a diagnosis or treatment.
  • Expectations are to move this research into the clinic and provide physicians with better tools to more quickly and accurately find and treat these diseases.
  • Such initiatives align with TLIs work in the chronic illness sector and will help patients avoid the disabling long-term effects of infection.
  • TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment.

FSD Pharma Reports 2018 Year-End Results

Retrieved on: 
Monday, May 6, 2019
Health, Alternative medicine, Pharmaceutical, Managed care, Pharma

FSD Pharma Inc. (CSE:HUGE)(OTC:FSDDF) (FRA:0K9) (FSD Pharma, FSDor the Company)today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018.

Key Points: 
  • FSD Pharma Inc. (CSE:HUGE)(OTC:FSDDF) (FRA:0K9) (FSD Pharma, FSDor the Company)today reported its financial and operational results for the fourth quarter and fiscal year-ended December 31, 2018.
  • During the year ended December 31, 2018, the Company used net cash of $18,489,903 in operating activities (2017 - $149,865).
  • The Company had a net increase in cash of $16,394,944 during the year ended December 31, 2018 (2017 - $4,709,907).
  • FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

Tilray, Inc. to Present at the BMO Farm to Market Conference

Retrieved on: 
Friday, May 3, 2019
Health, Alternative medicine, Natural Resources, Agriculture, Retail, Research, Tobacco, Science, Medicinal plants, Medicine, Entheogens, Euphoriants, Herbalism, Health sciences, Health, Tilray, Cannabis, Brendan Kennedy, Medical cannabis, Legality of cannabis

(Tilray or the Company) (Nasdaq: TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that Brendan Kennedy, President and Chief Executive Officer, and Mark Castaneda, Chief Financial Officer and Treasurer, will present at the BMO Farm to Market Conference.

Key Points: 
  • (Tilray or the Company) (Nasdaq: TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that Brendan Kennedy, President and Chief Executive Officer, and Mark Castaneda, Chief Financial Officer and Treasurer, will present at the BMO Farm to Market Conference.
  • The presentation will be on Thursday, May 16, 2019 at 2:10 p.m.
  • ET and the simultaneous, live webcast will be available on the Investors section of the Companys website at www.tilray.com .
  • Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.

Pinnacle Treatment Centers Acquires Addiction Medicine Care of Columbus, OH

Retrieved on: 
Thursday, May 2, 2019
Health, Alternative medicine, Mental health, Abnormal psychology, Substance-related disorders, Substance abuse, Addiction, Alcohol abuse, Drug rehabilitation, Substance dependence

Pinnacle Treatment Centers (PTC), a leader in providing accessible treatment for substance use disorders, announced today it has acquired Addiction Medicine Care (AMC) of Columbus, an office-based opioid treatment program (OBOT) located at 6434 E. Main Street, Reynoldsburg, Ohio.

Key Points: 
  • Pinnacle Treatment Centers (PTC), a leader in providing accessible treatment for substance use disorders, announced today it has acquired Addiction Medicine Care (AMC) of Columbus, an office-based opioid treatment program (OBOT) located at 6434 E. Main Street, Reynoldsburg, Ohio.
  • Pinnacle is one of a select few treatment facilities to provide underserved communities with affordable substance abuse treatment and the option of outpatient care.
  • Pinnacles 25+ programs in Ohio, which include a residential drug and alcohol addiction treatment center, Recovery Works Columbus, exemplify an integrated ambulatory model of care.
  • Pinnacle Treatment Centers Network is a recognized leader in comprehensive substance use services.

The Global Medical Cannabis Market is Projected to Reach $44.4 Billion by 2024, Growing at a CAGR of 22.9% - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 2, 2019
Health, Alternative medicine, Health, Herbalism, Medicinal plants, Medicine, Entheogens, Articles, Cannabis, Cannabis smoking, Medical cannabis

The "Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • The global medical cannabis market size was estimated to reach a value of US$ 13.4 Billion in 2018.
  • The market is further expected to reach value of US$ 44.4 Billion by 2024, exhibiting a CAGR of 22.9% during 2019-2024.
  • Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction.